Harrisburg-based Life Sciences Greenhouse of Central Pennsylvania has poured an additional $500,000 into one of the life-sciences companies in its investment portfolio.
The company is MacuLogix Inc., based in Derry Township. It is the developer of AdaptDx, an FDA-approved device that aids in early detection of age-related macular degeneration (AMD).
The cash infusion, announced Wednesday, brings the greenhouse’s investment in MacuLogix to over $2 million. The greenhouse was created in 2002 to invest in biotech firms in the region.
AMD, which affects more than 14 million Americans, is the leading cause of adult blindness. About 25 percent of cases go undiagnosed by primary eye care professionals, said MacuLogix co-founder and chief technology officer Gregory R. Jackson.
“We can, and should, do better,” Jackson said. “The AdaptDx technology makes early detection not just easier, but faster and more reliable as well.”
The technology enables eye care professionals to diagnose, monitor and treat age-related macular degeneration before vision loss occurs. It works by measuring a patient’s dark adaptation function, the recovery of vision when going from daylight to darkness, company officials said.
“MacuLogix is filling an unmet need in health care while creating high-quality jobs here in Central Pennsylvania,” said council president and CEO, Mel Billingsley, PhD. “The company’s prospects for growth and the potential to save the eyesight of millions, combined with the continued confidence of our co-investors, made further investment in MacuLogix an easy choice for LSGPA.”